Navigation Links
Case Western Reserve awarded $4.7 million from Defense Advanced Research Projects Agency
Date:7/30/2010

CLEVELAND July 30, 2010 Jonathan Stamler, MD, Director of the Institute for Transformative Molecular Medicine and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at the Case Western Reserve University and University Hospitals Harrington-McLaughlin Heart & Vascular Institute, has recently received a $4.7 million contract from the Defense Advanced Research Projects Agency (DARPA) to fund the development of a new class of drugs that will selectively dilate blood cells under hypoxia (lack of oxygen in the body's tissues) and thereby enhance soldiers' performance at high altitude.

"Our blood carries less oxygen at high altitudes," said Dr. Stamler. "And there is not much we can do about it. But if we could improve blood flow in tissues we could deliver more oxygen regardless of how much oxygen the blood carries."

Development of any method to enhance tissue oxygenation at high altitudes must consider the distinction between blood O2 content (how much oxygen the blood carries) and red blood cell (RBC) O2 delivery (primarily a function of blood flow). Oxygen delivery is controlled by a gas called nitric oxide, which is released from RBCs under hypoxia. Nitric oxide dilates blood vessels and thereby improves blood flow.

It's anticipated that the grant will generate new physiologic information on high-altitude adaption and new therapeutic interventions to treat patients suffering from conditions where oxygen delivery is impaired, including heart failure, ischemic heart disease, stroke, sickle cell disease and diabetes.

The study will involve a transdisciplinary team including the department of anesthesia, the division of pulmonary medicine, and the Harrington-McLaughlin Cardiovascular Institute at University Hospitals Case Medical Center, Case Western Reserve School of Medicine's primary clinical affiliate.


'/>"/>

Contact: Christina DeAngelis
christina.deangelis@case.edu
216-368-3635
Case Western Reserve University
Source:Eurekalert

Page: 1

Related biology news :

1. UT Southwestern researchers use novel sperm stem-cell technique to produce genetically modified rats
2. Temperature and salt levels of the Western Mediterranean are on the increase
3. UT Southwestern researchers find mechanism that may stop E. coli from developing in cattle
4. UT Southwestern researchers identify key molecular step to fighting off viruses
5. Case Western Reserve team discovers smart insulin molecule
6. UT Southwesterns BioCenter driving biotech, medical innovation in North Texas
7. New brain nerve cells key to stress resilience, UT Southwestern researchers find
8. UT Southwestern student receives fellowship from Howard Hughes Medical Institute
9. UT Southwestern researchers find clues to TB drug resistance
10. American pika are thriving in the Sierra Nevada and southwestern Great Basin
11. Plant breeding helps revive western rangelands
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/22/2017)... 2017 Optimove , provider of ... such as 1-800-Flowers and AdoreMe, today announced two ... Replenishment. Using Optimove,s machine learning algorithms, these features ... replenishment recommendations to their customers based not just ... customer intent drawn from a complex web of ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... -- Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund ... to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... USA ) and the US National Institutes of Health. ... ... ...
(Date:3/27/2017)... , March 27, 2017 The new ... a comprehensive library of reports on Valero Energy , ... fuels and petrochemical industries. ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO) ... production to go green. Ethanol today, even though touted as ...
(Date:3/27/2017)... DIEGO , March 27, 2017  Trovagene, Inc. ... that its Chief Executive Officer, Bill Welch , ... April 4, 2017 at 9:00 AM EDT at the ... .  Bill Welch, and Chief Scientific Officer, Mark ... with investors during the conference.   The presentation ...
(Date:3/24/2017)... MARIETTA, Ga. , March 24, 2017 ... and biopharmaceutical company utilizing human placental tissue allografts and ... therapies for multiple sectors of healthcare, announced today  that ... New York , NY.  Parker H. ... , Chief Financial Officer, Christopher M. Cashman , ...
Breaking Biology Technology: